Ventilation pneumonitis

Summary

Ventilation pneumonitis (MONDO:0001255) is a disease and 4 clinical trials. Top therapeutic interventions include aspirin. A subtype of hypersensitivity pneumonitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ventilation pneumonitis
Mondo ID	MONDO:0001255
DOID	DOID:11289
ICD-11	1414909625
SNOMED CT	195990006
UMLS	C0155891
MedGen	510127
GARD	0022909
Is cancer (heuristic)	no

Also known as: humidifier lung · humidifiers lung · ventilation systems lung

Disease family

This is a subtype of hypersensitivity pneumonitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › allergic respiratory disease › hypersensitivity pneumonitis › ventilation pneumonitis

Related subtypes (13): bagassosis, farmer’s lung disease, malt worker’s lung, cork-handlers’ disease, maple bark strippers’ lung, bird fancier’s lung, mushroom workers’ lung, sick building syndrome, hypersensitivity pneumonitis, familial, idiopathic chronic eosinophilic pneumonia, house allergic alveolitis, non-fibrotic hypersensitivity pneumonitis, fibrotic hypersensitivity pneumonitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06719258	Not specified	RECRUITING	Evaluation of Gas Humidification Practices in Patients Under Invasive Mechanical Ventilation
NCT04142827	Not specified	UNKNOWN	The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX)
NCT04390360	Not specified	UNKNOWN	Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction
NCT04425863	Not specified	COMPLETED	Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ASPIRIN	4	1